 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || VT301 / VT BIO, VT301 / ViThera
P1 data, Preclinical, Journal: A preclinical and phase I clinical study of ex vivo-expanded amyloid beta-specific human regulatory T cells in Alzheimer's disease. (Pubmed Central) - Dec 20, 2024
P1
This study suggests that hTregs may modulate Alzheimer's disease pathology by suppressing neuroinflammation, while VT301 shows promise as a safe treatment option. However, further research is necessary to confirm its clinical efficacy and optimize treatment strategies.
- VT301 / VT BIO, VT301 / ViThera
A NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE USING AMYLOID ΒETA-SPECIFIC HUMAN REGULATORY T CELLS TO CONTROL MICROGLIA ACTIVATION IN 3XTG MOUSE BRAIN. () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1559;
Here we confirm whether expanded amyloid-beta (Aβ)-specific Tregs with bvPLA2 in vitro (designated Ag-hTreg, VT301) exhibits efficacy as a therapeutic agent for neuro-inflammation. Therefore, our finding opens up the possibility of the clinical application using Treg as a cell therapy for Alzheimer's disease or microglia-related neuroinflammatory diseases.
- || VT301 / VT BIO, VT301 / ViThera
New P1 trial: A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease (clinicaltrials.gov) - Aug 22, 2021
P1, N=12, Recruiting, Sponsor: VTBIO Co. LTD
- | VT301 / VT BIO
Trial completion date, Trial initiation date, Trial primary completion date: A Safety and Tolerability Study of GB301 (clinicaltrials.gov) - Aug 4, 2019
P1/2, N=20, Not yet recruiting, Sponsor: GMP BIO Co., LTD.
Therefore, our finding opens up the possibility of the clinical application using Treg as a cell therapy for Alzheimer's disease or microglia-related neuroinflammatory diseases. Trial completion date: Jan 2020 --> Dec 2021 | Initiation date: Jun 2019 --> Dec 2019 | Trial primary completion date: Dec 2019 --> Dec 2020
- || VT301 / VT BIO
New P1/2 trial: A Safety and Tolerability Study of GB301 (clinicaltrials.gov) - Mar 6, 2019
P1/2, N=20, Not yet recruiting, Sponsor: GMP BIO Co., LTD.